As of November 10, 2026, Oruka Therapeutics, Inc. is a publicly traded company (Nasdaq: ORKA). The largest holder reporting an active stake on Schedule 13D is Fairmount Funds Management LLC, at 19.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Venrock Healthcare Capital Partners III, L.P. (7.4%), BlackRock (6.6%), Capital World Investors (5.6%) (Schedule 13D/A, July 1, 2026).
Is this your company?
About to sign with, pay or invest in Oruka Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Oruka Therapeutics, Inc. a real, registered company?
- Oruka Therapeutics, Inc. files with the SEC under CIK 907654 (its SEC filings).
- Its shares are listed under the ticker ORKA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Menlo Park, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ORUKA THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RTW Investments (filed 2026-08-14).
Who are Oruka Therapeutics, Inc.'s owners and officers?
Oruka Therapeutics, Inc.: incorporated in Delaware; business address in Menlo Park, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | Rtw Investments, LP | 5.2% |
| Schedule 13G/A, 2026-08-14 | Venrock Healthcare Capital Partners Iii, L.P. | 7.4% |
| Schedule 13G/A, 2026-08-14 | Viking Global Investors LP | 2.5% |
| Schedule 13G, 2026-08-12 | Capital World Investors | 5.6% |
| Schedule 13D/A, 2026-07-01 | Fairmount Funds Management LLC | 19.5% |
| Schedule 13G/A, 2026-05-15 | Viking Global Investors LP | 5.3% |
| Schedule 13D/A, 2026-05-04 | Fairmount Funds Management LLC | 19.99% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Rtw Investments, LP | 4.3% |
| Schedule 13G/A, 2026-02-13 | Deep Track Capital, LP | 4.47% |
| Schedule 13G, 2026-01-30 | The Vanguard Group | 5.06% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 6.6% |
Questions about who owns Oruka Therapeutics, Inc.
Who owns Oruka Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Oruka Therapeutics, Inc.: Fairmount Funds Management LLC (19.5%, Schedule 13D/A, filed 2026-07-01), Venrock Healthcare Capital Partners Iii, L.P. (7.4%, Schedule 13G/A, filed 2026-08-14), Blackrock, Inc. (6.6%, Schedule 13G, filed 2026-01-21), Capital World Investors (5.6%, Schedule 13G, filed 2026-08-12) and Rtw Investments, LP (5.2%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Oruka Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Oruka Therapeutics, Inc. on this page are Fairmount Funds Management LLC (19.5%), Venrock Healthcare Capital Partners Iii, L.P. (7.4%) and Blackrock, Inc. (6.6%).
When did Fairmount Funds Management LLC buy into Oruka Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2026-05-04, reporting 19.99%; its latest, Schedule 13D/A filed 2026-07-01, reports 19.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Oruka Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Oruka Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Oruka Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Oruka Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- VHCP Management EG, LLC, a 10% owner: 4,148,428 shares (6.1% of shares outstanding), held indirectly through a funds, on a joint filing (Form 4, 2025-02-27).
- VHCP Co-Investment Holdings III, LLC, a 10% owner: 4,148,428 shares (6.1% of shares outstanding), held indirectly through a funds, on a joint filing (Form 4, 2025-02-27).
- Venrock Healthcare Capital Partners III, L.P., a 10% owner: 4,148,428 shares (6.1% of shares outstanding), held indirectly through a funds, on a joint filing (Form 4, 2025-02-27).
- VHCP Management III, LLC, a 10% owner: 4,148,428 shares (6.1% of shares outstanding), held indirectly through a funds, on a joint filing (Form 4, 2025-02-27).
- , a 10% owner: 4,148,428 shares (6.1% of shares outstanding), held indirectly through a funds, on a joint filing (Form 4, 2025-02-27).
Shares outstanding: 67,822,359 as of 2026-10-31, from the company's latest SEC cover page.
How much has Oruka Therapeutics, Inc. raised?
Latest IPO step: Oruka Therapeutics, Inc. filed to go public (S-1, 2024-11-14).
IPO filings: S-1, 2024-11-14; ticker ORKA on Nasdaq Global Market.
Keep reading
More on Oruka Therapeutics, Inc. and the records around it.
Oruka Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/oruka-therapeutics